91 results on '"Huhn, Andrew S."'
Search Results
2. Sex as a Biological Variable and Gender as a Social Construct in the Treatment of Opioid Use Disorder
3. COVID-19–Related Financial Hardship Is Associated With Depression and Anxiety in Substance Use Treatment Across Gender and Racial Groups
4. A brief measure of non-drug reinforcement: Association with treatment outcomes during initial substance use recovery
5. The association of pain impact and sleep disruption with opioid withdrawal during opioid‐use disorder treatment
6. Knowledge, Preference, and Adverse Effects of Xylazine Among Adults in Substance Use Treatment
7. Intersectional Risk and the Significant Gap in Care for Persons with Co-occurring Chronic Pain and Opioid Withdrawal
8. Suvorexant alters dynamics of the sleep-EEG power spectrum and depressive symptom trajectories during inpatient opioid withdrawal
9. Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype–genotype assessment
10. Transgender individuals are at higher risk for suicidal ideation and preparation than cisgender individuals in substance use treatment
11. Within subject, double blind, examination of opioid sensitivity in participant-reported, observed, physiologic, and analgesic outcomes.
12. Patterns of demoralization and anhedonia during early substance use disorder treatment and associations with treatment attrition
13. Pain catastrophizing moderates the relationship between chronic pain and insomnia severity in persons with opioid use disorder
14. Promoting Sleep Health to Mitigate the Risk of Non-medical Opioid Use and Opioid-related Adverse Events
15. Predictors of Suicidal Ideation During Residential Substance Use Treatment
16. Within-subject, double-blind, randomized, placebo-controlled evaluation of combining the cannabinoid dronabinol and the opioid hydromorphone in adults with chronic pain
17. Fentanyl Absorption, Distribution, Metabolism, and Excretion: Narrative Review and Clinical Significance Related to Illicitly Manufactured Fentanyl
18. Latent patterns of sleep disturbance, pain impact, and depressive symptoms in residential substance use treatment
19. The impact of opioid-stimulant co-use on tonic and cue-induced craving
20. Operational definition of precipitated opioid withdrawal
21. Patterns of polysubstance use and clinical comorbidity among persons seeking substance use treatment: An observational study
22. A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal.
23. Can initial experiences with drugs predict future drug abuse risks?
24. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder
25. Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.
26. Wireless electroencephalography (EEG) to monitor sleep among patients being withdrawn from opioids: Evidence of feasibility and utility.
27. Pharmacological interventions for insomnia disorder in adults
28. The association of chronic pain and opioid withdrawal in men and women with opioid use disorder
29. Patient perceptions of higher-dose naloxone nasal spray for opioid overdose
30. Objective sleep outcomes in randomized-controlled trials in persons with substance use disorders: A systematic review
31. Patient-reported sleep outcomes in randomized-controlled trials in persons with substance use disorders: A systematic review
32. Opioid Use Disorder Treatment in the Fentanyl Era
33. Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper
34. Positive associations between cannabis and alcohol use polygenic risk scores and phenotypic opioid misuse among African-Americans
35. Commentary on Zolopa et al.: Trauma as an impediment to successful aging and a precipitant of opioid and stimulant use among older adults
36. Evaluation of Stigma Related to Perceived Risk for Coronavirus-19 Transmission Relative to the Other Stigmatized Conditions Opioid Use and Depression
37. Substance Use in the Performing Artist with Chronic Pain
38. Worsening sleep quality across the lifespan and persistent sleep disturbances in persons with opioid use disorder
39. Latent trajectories of anxiety and depressive symptoms among adults in early treatment for nonmedical opioid use
40. Adults With Opioid and Methamphetamine Co-use Have Lower Odds of Completing Short-Term Residential Treatment Than Other Opioid Co-use Groups: A Retrospective Health Services Study
41. Evidence of Buprenorphine-precipitated Withdrawal in Persons Who Use Fentanyl
42. Attitudes Toward Organ Donation for Persons Who Have a Substance Use Disorder Relative to Other Health Conditions
43. Integration of Patient-reported Outcomes Assessment Into Routine Care for Patients Receiving Residential Treatment for Alcohol and/or Substance Use Disorder
44. Reregulation of cortisol levels and sleep in patients with prescription opioid use disorder during long-term residential treatment
45. Comprehensive pain management as a frontline treatment to address the opioid crisis
46. Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone
47. Clinical correlates of drug‐related dreams in opioid use disorder
48. Shared Genetic Etiology between Cortical Brain Morphology and Tobacco, Alcohol, and Cannabis Use
49. Promoting harm reduction as a treatment outcome in substance use disorders.
50. The discounting of death: Probability discounting of heroin use by fatal overdose likelihood and drug purity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.